Zacks Investment Research Lowers Advaxis (NASDAQ:ADXS) to Sell

Zacks Investment Research cut shares of Advaxis (NASDAQ:ADXS) from a hold rating to a sell rating in a report issued on Monday morning, Zacks.com reports.

According to Zacks, “Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body’s immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company’s products in development include Lovaxin C and Lovaxin B, Lovaxin P. “

A number of other research analysts have also issued reports on the company. HC Wainwright reiterated a neutral rating on shares of Aerpio Pharmaceuticals in a report on Wednesday, June 12th. ValuEngine lowered Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd.



Shares of ADXS traded down $0.16 during midday trading on Monday, hitting $1.55. 264,400 shares of the stock were exchanged, compared to its average volume of 322,170. Advaxis has a 52-week low of $1.50 and a 52-week high of $24.60. The stock’s fifty day moving average is $2.41. The firm has a market cap of $8.92 million, a price-to-earnings ratio of -0.08 and a beta of 3.30.

Large investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its holdings in shares of Advaxis by 5,970.3% in the fourth quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 553,031 shares during the period. Two Sigma Investments LP boosted its holdings in Advaxis by 2,468.2% during the fourth quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 355,415 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in Advaxis by 3.1% during the fourth quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 43,368 shares during the last quarter. Hedge funds and other institutional investors own 24.40% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

See Also: What is meant by buying and selling pressure?

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.